(NSIS-B) Novonesis (Novozymes) - Ratings and Ratios
Enzymes, Proteins, Microorganisms, Biosolutions, Biocatalysis
NSIS-B EPS (Earnings per Share)
NSIS-B Revenue
Description: NSIS-B Novonesis (Novozymes)
Novozymes A/S is a leading biotech company that produces and sells industrial enzymes, functional proteins, and microorganisms globally, operating in multiple regions including Europe, North America, Asia Pacific, and others. The company offers a diverse range of biosolutions across various industries, including food and beverage, industrial hygiene, agriculture, animal health, and human health.
The companys product portfolio is vast, catering to different sectors such as dairy, baking, beverage, and meat processing, as well as providing solutions for biofuel production, wastewater treatment, and biogas generation. Novozymes enzymes and microorganisms are used to improve efficiency, reduce costs, and enhance product quality in various industrial processes.
Key Performance Indicators (KPIs) that could be relevant for evaluating Novozymes performance include revenue growth, gross margin ratio, operating profit margin, return on equity (ROE), and dividend yield. The companys ability to innovate and expand its product offerings in emerging markets, such as biofuels and biorefinery, could be crucial for its long-term growth. Additionally, Novozymes commitment to sustainability and reducing environmental impact could be an important factor in its appeal to environmentally conscious investors.
From a financial perspective, Novozymes market capitalization stands at approximately DKK 214 billion, with a forward price-to-earnings ratio of 30.12, indicating a relatively high valuation. However, the companys strong brand presence, diversified product portfolio, and commitment to research and development could justify a premium valuation. Investors may also be interested in monitoring Novozymes ability to maintain its pricing power, manage raw material costs, and expand its presence in growing markets.
Overall, Novozymes strong market position, diversified product portfolio, and commitment to innovation and sustainability make it an attractive investment opportunity for those looking to gain exposure to the specialty chemicals sector.
NSIS-B Stock Overview
| Market Cap in USD | 28,399m |
| Sub-Industry | Specialty Chemicals |
| IPO / Inception |
NSIS-B Stock Ratings
| Growth Rating | 3.65% |
| Fundamental | 63.5% |
| Dividend Rating | 15.7% |
| Return 12m vs S&P 500 | -24.6% |
| Analyst Rating | - |
NSIS-B Dividends
| Dividend Yield 12m | 1.55% |
| Yield on Cost 5y | 1.90% |
| Annual Growth 5y | -5.29% |
| Payout Consistency | 97.3% |
| Payout Ratio | 145.0% |
NSIS-B Growth Ratios
| Growth Correlation 3m | -97.1% |
| Growth Correlation 12m | -2.6% |
| Growth Correlation 5y | 11.9% |
| CAGR 5y | 3.64% |
| CAGR/Max DD 5y | 0.08 |
| Sharpe Ratio 12m | -0.30 |
| Alpha | -15.08 |
| Beta | 0.142 |
| Volatility | 32.13% |
| Current Volume | 920.9k |
| Average Volume 20d | 465.7k |
| Stop Loss | 393.4 (-3%) |
| Signal | -1.59 |
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income (904.5m TTM) > 0 and > 6% of Revenue (6% = 1.00b TTM) |
| FCFTA 0.22 (>2.0%) and ΔFCFTA 14.28pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 4.63% (prev 12.29%; Δ -7.66pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.30 (>3.0%) and CFO 4.54b > Net Income 904.5m (YES >=105%, WARN >=100%) |
| Net Debt (1.45b) to EBITDA (2.25b) ratio: 0.64 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.66 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (466.2m) change vs 12m ago 67.47% (target <= -2.0% for YES) |
| Gross Margin 43.95% (prev 54.32%; Δ -10.37pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 77.07% (prev 63.04%; Δ 14.02pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| error: Interest Coverage Ratio cannot be calculated (needs EBITDA TTM and Interest Expense TTM) |
Altman Z'' 6.35
| (A) 0.05 = (Total Current Assets 1.95b - Total Current Liabilities 1.17b) / Total Assets 15.06b |
| (B) 0.74 = Retained Earnings (Balance) 11.20b / Total Assets 15.06b |
| (C) 0.08 = EBIT TTM 1.67b / Avg Total Assets 21.72b |
| (D) 2.93 = Book Value of Equity 11.20b / Total Liabilities 3.83b |
| Total Rating: 6.35 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 63.51
| 1. Piotroski 6.0pt = 1.0 |
| 2. FCF Yield 12.65% = 5.0 |
| 3. FCF Margin 19.48% = 4.87 |
| 4. Debt/Equity 0.15 = 2.49 |
| 5. Debt/Ebitda 0.75 = 2.07 |
| 6. ROIC - WACC 3.23% = 4.04 |
| 7. RoE 1.94% = 0.16 |
| 8. Rev. Trend -42.08% = -2.10 |
| 9. Rev. CAGR -39.90% = -2.50 |
| 10. EPS Trend -47.46% = -1.19 |
| 11. EPS CAGR -2.64% = -0.33 |
What is the price of NSIS-B shares?
Over the past week, the price has changed by +1.17%, over one month by -7.05%, over three months by -12.87% and over the past year by -11.82%.
Is Novonesis (Novozymes) a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of NSIS-B is around 383.78 DKK . This means that NSIS-B is currently overvalued and has a potential downside of -5.38%.
Is NSIS-B a buy, sell or hold?
What are the forecasts/targets for the NSIS-B price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 496.9 | 22.5% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 419.1 | 3.3% |
NSIS-B Fundamental Data Overview
Market Cap EUR = 24.33b (181.58b DKK * 0.134 DKK.EUR)
CCE Cash And Equivalents = 249.5m EUR (Cash only, last quarter)
P/E Trailing = 52.9172
P/E Forward = 25.8398
P/S = 44.7511
P/B = 2.1661
P/EG = 0.2219
Beta = 0.548
Revenue TTM = 16.74b EUR
EBIT TTM = 1.67b EUR
EBITDA TTM = 2.25b EUR
Long Term Debt = 1.27b EUR (from longTermDebt, last quarter)
Short Term Debt = 429.9m EUR (from shortLongTermDebt, last quarter)
Debt = 1.70b EUR (Calculated: Short Term 429.9m + Long Term 1.27b)
Net Debt = 1.45b EUR (from netDebt column, last quarter)
Enterprise Value = 25.78b EUR (24.33b + Debt 1.70b - CCE 249.5m)
Interest Coverage Ratio = unknown (Ebit TTM 1.67b / Interest Expense TTM 0.0)
FCF Yield = 12.65% (FCF TTM 3.26b / Enterprise Value 25.78b)
FCF Margin = 19.48% (FCF TTM 3.26b / Revenue TTM 16.74b)
Net Margin = 5.40% (Net Income TTM 904.5m / Revenue TTM 16.74b)
Gross Margin = 43.95% ((Revenue TTM 16.74b - Cost of Revenue TTM 9.38b) / Revenue TTM)
Tobins Q-Ratio = 2.30 (Enterprise Value 25.78b / Book Value Of Equity 11.20b)
Interest Expense / Debt = 1.77% (Interest Expense 30.0m / Debt 1.70b)
Taxrate = 26.68% (from yearly Tax Provision: 111.3m / 417.1m)
NOPAT = 1.22b (EBIT 1.67b * (1 - 26.68%))
Current Ratio = 1.66 (Total Current Assets 1.95b / Total Current Liabilities 1.17b)
Debt / Equity = 0.15 (Debt 1.70b / last Quarter total Stockholder Equity 11.23b)
Debt / EBITDA = 0.75 (Net Debt 1.45b / EBITDA 2.25b)
Debt / FCF = 0.52 (Debt 1.70b / FCF TTM 3.26b)
Total Stockholder Equity = 46.64b (last 4 quarters mean)
RoA = 6.01% (Net Income 904.5m, Total Assets 15.06b )
RoE = 1.94% (Net Income TTM 904.5m / Total Stockholder Equity 46.64b)
RoCE = 3.48% (Ebit 1.67b / (Equity 46.64b + L.T.Debt 1.27b))
RoIC = 9.43% (NOPAT 1.22b / Invested Capital 12.97b)
WACC = 6.20% (E(24.33b)/V(26.03b) * Re(6.54%)) + (D(1.70b)/V(26.03b) * Rd(1.77%) * (1-Tc(0.27)))
Shares Correlation 5-Years: -90.0 | Cagr: -0.27%
Discount Rate = 6.54% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 74.66% ; FCFE base≈2.80b ; Y1≈2.25b ; Y5≈1.54b
Fair Price DCF = 69.35 (DCF Value 28.56b / Shares Outstanding 411.9m; 5y FCF grow -23.52% → 3.0% )
Revenue Correlation: -42.08 | Revenue CAGR: -39.90%
Rev Growth-of-Growth: -52.72
EPS Correlation: -47.46 | EPS CAGR: -2.64%
EPS Growth-of-Growth: 29.76